Reported revenues fell by $440 million, or roughly 3%, which reflected slight operational growth of $9 million and the unfavorable impact of foreign exchange of $449 million. Operational growth was driven by key products such as Lyrica, Prevnar, Eliquis and Xeljanz in the United States.
Pfizer’s segments reported revenue, compared to the same quarter in the previous year, as:
- Global Innovative Pharma down 11% to $6.45 billion
- Global Established Pharma up 3% to $3.75 billion
- Global Vaccines 18% higher to $1.32 billion
- Consumer Healthcare up 1% to $953 million
- Global Oncology up 10% to $609 million
- Other down 35% to $83 million
Frank D’Amelio, CFO of Pfizer, gave guidance for the year:
We are also providing our 2015 financial guidance, including ranges for reported revenues of $44.5 to $46.5 billion and for adjusted diluted EPS of $2.00 to $2.10. Our guidance for reported revenues reflects the anticipated negative impact of $3.5 billion due to recent and expected product losses of exclusivity as well as $2.8 billion as a result of recent adverse changes in essentially all foreign exchange rates relative to the U.S. dollar compared to foreign exchange rates from last year, partially offset by anticipated revenue growth from certain other products.
ALSO READ: The Bull and Bear Case for Pfizer in 2015
Early in January, Deutsche Bank maintained a Buy rating for Pfizer with a $35.00 price target, implying upside of 6.7% from Monday’s close. The highest listed analyst price target is $41.00, which implies an upside of 25%.
Shares of Pfizer closed Monday up 1% at $32.80. In Tuesday’s early bird indications, shares were down roughly 1% at $32.48. The stock has a consensus analyst price target of $34.46 and a 52-week trading range of $27.51 to $33.50.
Top Gaining Stocks
Top Losing Stocks